Latest Breaking News On - Harout semerjian - Page 7 : comparemela.com

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule

06.12.2021 - GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and the Alliance for Clinical Trials in Oncology, have completed . Seite 1

GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs

GlycoMimetics, inc (GLYC) Q3 2021 Earnings Call Transcript

GLYC earnings call for the period ending September 30, 2021.

GlycoMimetics, inc (GLYC) Q3 2021 Earnings Call Transcript

GLYC earnings call for the period ending September 30, 2021.

GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript